The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2017;10(1): 4‑10

Read: 3314 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2017;10(1):4‑10. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Giugliano R.P., Sabatine M.S. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 2015;65:2638—2651.
  2. Blom D.J., Hala T., Bolognese M., et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809—1819.
  3. Robinson J.G., Nedergaard B.S., Rogers W.J., et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870—1882.
  4. Koren M.J., Lundqvist P., Bolognese M., et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2531—2540.
  5. Stroes E., Colquhoun D., Sullivan D., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2541—2548.
  6. Raal F.J., Stein E.A., Dufour R., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331—340. 
  7. Cohen J.C., Boerwinkle E., Mosley T.H. Jr, Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264—1272.
  8. Kathiresan S. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med 2008;358:2299—2300.
  9. Sabatine M.S., Giugliano R.P., Wiviott S.D, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500—1509.
  10. Robinson J.G., Farnier M., Krempf M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489—1499.
  11. .Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:Suppl 2:S1—S45.
  12. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495—1504.
  13. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425—1435.
  14. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387—2397.
  15. Giugliano R.P., Cannon C., Blazing M., et al. Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. J Am Coll Cardiol 2015;65:Suppl:A4. abstract.
  16. Nicholls S.J., Puri R., Anderson T., et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 2016;316:2373—2384.
  17. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016;68:92— 125.
  18. Landmesser U., John Chapman M., Farnier M., et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016 October 27 (Epub ahead of print).
  19. Sabatine M.S. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J 2017 January 21 (Epub ahead of print).
  20. Collins R., Reith C., Emberson J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532—2561.
  21. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351—364.
  22. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237—1245.
  23. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia — report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946—955.
  24. The Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670—1681.
  25. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383—1389.
  26. Braunwald E., Morrow D.A. Unstable angina: is it time for a requiem? Circulation 2013;127:2452—2457.
  27. Silverman M.G., Ference B.A., Im K., et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289—1297.
  28. Ference B.A., Robinson J.G., Brook R.D., et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016;375:2144—153.
  29. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735—742.
  30. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556—2564.
  31. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. Press release from Pfizer, New York, November 1, 2016 (http:// www.pfizer.com/news/press-release/ press-release-detail/pfizer_discontinues_ global_development_of_bococizumab_ its_investigational_pcsk9_inhibitor).
  32. Koren M.J., Sabatine M.S., Giugliano R.P., et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017 March 14 (Epub ahead of print).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.